Website
News25/Ratings12
News · 26 weeks63-27%
2025-10-262026-04-19
Mix4290d
- Insider23(55%)
- SEC Filings8(19%)
- Other6(14%)
- Analyst2(5%)
- Earnings2(5%)
- Leadership1(2%)
Latest news
25 items- ANALYSTInsulet downgraded by Citigroup with a new price targetCitigroup downgraded Insulet from Buy to Neutral and set a new price target of $230.00
- SECSEC Form DEFA14A filed by Insulet CorporationDEFA14A - INSULET CORP (0001145197) (Filer)
- SECSEC Form DEF 14A filed by Insulet CorporationDEF 14A - INSULET CORP (0001145197) (Filer)
- INSIDERSEC Form 4 filed by Panos Michael4 - INSULET CORP (0001145197) (Issuer)
- INSIDERSEC Form 3 filed by new insider Panos Michael3 - INSULET CORP (0001145197) (Issuer)
- INSIDERSEC Form 4 filed by Huffines Robert Luther4 - INSULET CORP (0001145197) (Issuer)
- PRInsulet to Announce First Quarter 2026 Financial Results on May 6, 2026Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929
- PRInsulet Appoints Mike Panos as Chief Commercial OfficerInsulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet's global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330524787/en/ "We have a significant growth opportunity in front of us, driven by strong clinical outcomes
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Insulet CorporationSCHEDULE 13G/A - INSULET CORP (0001145197) (Subject)
- SECInsulet Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - INSULET CORP (0001145197) (Filer)
- PRInsulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.Medical Device Correction impacts only specific lots of Omnipod® 5 Pods Customers can visit omnipod.com/check-pods to check lot numbers and request replacement Pods at no cost All other Omnipod® 5 Pods and Omnipod® products remain safe to use Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company") today initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring. This action applies to specific identified lots distributed in the United States, and all other Omnipod® 5 Pods and Omnipod® products remain safe to use. Insulet identified that certain Pods from specific lots
- PRInsulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 DiabetesOutcomes from EVOLUTION 2 study include 68% time in range with no boluses Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve outcomes, and redefine user and clinician experience Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has shared new clinical evidence related to the development of its first fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes. "Developing and bringing to market a fully closed-loop AID system for people with type 2 diabetes—one that delivers therapy effortl
- PRInsulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)Fully Closed-Loop System Feasibility Study to be presented at Insulet Symposium and in e-Poster during ATTD 2026 Real World Evidence of Settings Optimization in Omnipod 5 Users will also be shared Other activities include immersive multi-media education HUB, hands-on Omnipod product demonstrations led by clinical experts, and live podcast recordings Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will present new clinical evidence related to its first fully closed-loop (FCL) automated insulin delivery (AID) system for type 2 diabetes (T2D) at the 19th International Conference on
- SECInsulet Corporation filed SEC Form 8-K: Leadership Update8-K - INSULET CORP (0001145197) (Filer)
- INSIDERSVP, Global Operations Singh Prem covered exercise/tax liability with 269 shares, decreasing direct ownership by 4% to 6,891 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERSVP, Reg, Quality & Compliance Cousin Laetitia covered exercise/tax liability with 253 shares, decreasing direct ownership by 4% to 5,674 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERGroup VP, CAO and Controller Budden Lauren covered exercise/tax liability with 218 shares, decreasing direct ownership by 2% to 8,526 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERSVP and General Counsel Kapples John W. covered exercise/tax liability with 605 shares, decreasing direct ownership by 2% to 27,514 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDEREVP and COO Benjamin Eric covered exercise/tax liability with 912 shares, decreasing direct ownership by 4% to 23,600 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERSVP, Global Operations Singh Prem was granted 2,140 shares and covered exercise/tax liability with 138 shares, increasing direct ownership by 39% to 7,160 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERGroup VP, CAO and Controller Budden Lauren was granted 611 shares and covered exercise/tax liability with 55 shares, increasing direct ownership by 7% to 8,744 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERSVP, Reg, Quality & Compliance Cousin Laetitia was granted 1,044 shares and covered exercise/tax liability with 111 shares, increasing direct ownership by 19% to 5,927 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERSVP and General Counsel Kapples John W. was granted 1,885 shares and covered exercise/tax liability with 263 shares, increasing direct ownership by 6% to 28,119 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDEREVP and COO Benjamin Eric was granted 3,822 shares and covered exercise/tax liability with 395 shares, increasing direct ownership by 16% to 24,512 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERSVP, Chief HR Officer Davis Lisa Blair was granted 2,140 shares, increasing direct ownership by 86% to 4,617 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)